Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.54 |
| ▸ | JAK1 | P23458 | 4/20 | 0.54 |
| ▸ | JAK3 | P52333 | 4/20 | 0.54 |
| ▸ | TYK2 | P29597 | 2/20 | 0.54 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | BRD2 | P25440 | 2/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 3/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632928 | 0.94 | JAK2 (0.54) | JAK2JAK1JAK3TYK2TNIK | |
| SCHEMBL1634250 | 0.93 | JAK2 (0.56) | JAK2JAK1JAK3TYK2TNIK | |
| SCHEMBL1634131 | 0.91 | JAK2 (0.58) | JAK2JAK1JAK3TYK2TNIK | |
| SCHEMBL1632726 | 0.91 | JAK2 (0.54) | JAK2JAK1JAK3TYK2TNIK | |
| SCHEMBL1632647 | 0.87 | LRRK2 (0.44) | JAK2JAK1JAK3BRD4BRD2 | |
| SCHEMBL1633277 | 0.87 | JAK2 (0.52) | JAK2JAK1JAK3TYK2TNIK | |
| SCHEMBL1632738 | 0.87 | JAK2 (0.59) | JAK2JAK1JAK3TYK2TNIK | |
| SCHEMBL1633875 | 0.86 | JAK2 (0.59) | JAK2JAK1JAK3TYK2TNIK | |
| SCHEMBL12724681 | 0.86 | JAK2 (0.54) | JAK2JAK1JAK3TYK2TNIK | |
| SCHEMBL1634146 | 0.86 | PTK2 (0.59) | JAK2JAK1JAK3TYK2TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | JAK2 1352/4885JAK1 2248/4885JAK3 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.